“It is in the Negev that Jewish scientific talent
and research ability shall be tested.”

The National Institute for Biotechnology in the Negev Ltd. (NIBN), a unique Bio accelerator located within Ben-Gurion University of the Negev (BGU), is the first self-organized, independent research entity established under the auspices of a University in Israel.

The NIBN was established as a company in November 2009 and its shareholders are BGU and the de Picciotto family.

NIBN is the home for accelerating BGU’s bio-applied translational discovery and research, through successful proof-of-concept and commercialization.

Research at the NIBN is focused in several key areas: Cancer, Neurodegenerative Diseases, Autoimmune and Metabolic Diseases, Applied Biotechnology, Infectious Diseases, Human Genetic Disorders, and AgBio. The decision to focus on these topics combines existing strengths and resources unique to the NIBN and BGU.

Located within Ben-Gurion University’s main campus in Beer-Sheva, the NIBN represents a framework that is distinct from existing academic models, yet incorporates the creative University setting and dedication to excellence in research, and creates an environment conducive to pioneering ideas.

The NIBN provides its researchers with state-of-the-art laboratories, research and manpower grants, infrastructure support units, as well as intellectual property strategy and guidance, project management, business development leadership and legal services provided by NIBN’s experienced professional management team.